ABC1000 Program

ABC1000 Program

Be the pioneer and join ABC1000 Program, now!

Discover how ABC (Age, Biomarkers and Clinical history) scores could provide more accurate stroke and bleeding risk stratification for patients with atrial fibrillation.

What are the ABC Scores?

ABC Scores (Age, Biomarkers, Clinical history) stroke and bleeding scores are personalized stroke and bleeding risk assessment scores that incorporate clinical variables and cardiovascular biomarkers Elecsys® GDF-15, Elecsys® NT-proBNP, Elecsys® cTnT-hs and hemoglobin to estimate risk of stroke/systemic embolic events and bleeding in patients with atrial fibrillation. All of those biomarkers have been CE marked for use in ABC Scores.

ABC Scores have better prognostic performance vs. standard of care (CHA2DS2-VASc and HAS-BLED) as they have better discriminative ability and net reclassification benefit validated and calibrated in over 37’000 patients from six major pharmaceutical trials. This is expressed by improved C-statistics of ABC Scores vs. standard of care risk tools like CHA2DS2-VASc and HAS-BLED1-5.

Patient outcomes (clinical utility) and economic utility data for ABC Scores is currently in generation with the prospective, interventional, randomized clinical trial called ‘ABC-AF’6. Possible outcomes of this trial could indicate improvements in overall patient management and cost effectiveness. The results will be published in 2026.


About ABC1000 Program


ABC1000 is a commercial product evaluation program offered to physicians who diagnose and treat patients with atrial fibrillation and would like to try the novel ABC stroke and ABC bleeding scores to risk stratify them. Roche Diagnostics aims to touch the lives of approximately 1000 atrial fibrillation patients with this initiative.

Within the framework of the ABC1000 Program, the physicians and their institutions will benefit from getting access to innovative risk assessment tools, including a new biomarker GDF-15. The physicians are asked to try out the ABC Scores in their daily practice and assess their experience and satisfaction with them. ABC Scores can be used along the current standard of care methods and are not supposed to replace them for the duration of the Program. 

This product evaluation program is applicable only in countries where Elecsys® GDF‑15, Elecsys® NT‑proBNP and Elecsys® cTnT‑hs have regulatory approval..

What does participation in the ABC1000 Program entail?

icon test tube

Roche Elecsys® GDF-15, Elecsys® NT-proBNP and Elecsys® cTnT-hs kits, needed to implement ABC Scores, will be provided to the institution/laboratory physician works with, in exchange for an evaluation from the physician

icon survey

The evaluation of ABC Scores will be done via an online survey

icon white paper

Physicians will be contributing to a global white paper that would consolidate the results from all participants (encompassing approximately 1000 patient cases)*

icon advisory board

Provided sufficient data collection, a commercial advisory board may be organized with participating physicians to discuss the outcomes of the Program and encourage them to share their experience with ABC Scores and the white paper at educational events and congresses**

*Subject to change, depending on the quantity and quality of feedback submitted in the Evaluation Survey.

**Participation in educational events or congresses in regards to the ABC1000 Program could be sponsored by Roche upon individual agreements. Physicians would be remunerated for their speaking or commercial advisory board engagements accordingly (subject of a separate agreement).

Register now


Are you a physician interested in trying the novel ABC Scores and participating in the ABC1000 Product Evaluation Program?

Please apply to our Program by filling out the form and a Roche representative will contact you.

Tack, meddelandet har nu skickats!


  1. Hijazi Z, et al. Lancet 2016;387(10035):2302-2311;
  2. Hijazi Z, et al. Eur Heart J 2016;37(20):1582-1590;
  3. Berg DD, et al. Circulation 2019;139(6):760-771;
  4. Oyama K, et al. Eur Heart J 2021;42(17):1698-1706;
  5. Benz AP, et al. Circulation 2021;143(19):1863–1873;
  6. website [Internet; cited 2022 Oct 4].  Available from:;